CN114010783A - Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof - Google Patents
Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114010783A CN114010783A CN202111291736.5A CN202111291736A CN114010783A CN 114010783 A CN114010783 A CN 114010783A CN 202111291736 A CN202111291736 A CN 202111291736A CN 114010783 A CN114010783 A CN 114010783A
- Authority
- CN
- China
- Prior art keywords
- boron
- rich
- cof
- organic framework
- covalent organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 145
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 144
- 238000002360 preparation method Methods 0.000 title claims abstract description 104
- 230000008685 targeting Effects 0.000 title claims abstract description 72
- 239000013310 covalent-organic framework Substances 0.000 title claims abstract description 60
- 239000000463 material Substances 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 54
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 27
- 239000002135 nanosheet Substances 0.000 claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 21
- 201000007983 brain glioma Diseases 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 9
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 9
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000004729 solvothermal method Methods 0.000 claims description 5
- 239000013076 target substance Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- XXJYLEWWCJOUNU-UHFFFAOYSA-N B(O)OBO.C(C1=CC=C(C(=O)O)C=C1)(=O)O Chemical compound B(O)OBO.C(C1=CC=C(C(=O)O)C=C1)(=O)O XXJYLEWWCJOUNU-UHFFFAOYSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960001476 pentoxifylline Drugs 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical group N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 claims description 2
- AEGSIYIIMVBZQU-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxy-2-sulfanylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AEGSIYIIMVBZQU-CIUDSAMLSA-N 0.000 claims description 2
- HGDCPUWNNFKWOU-UHFFFAOYSA-N B(O)(O)OB(O)O.C(C1=CC=C(C(=O)O)C=C1)(=O)O Chemical compound B(O)(O)OB(O)O.C(C1=CC=C(C(=O)O)C=C1)(=O)O HGDCPUWNNFKWOU-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 108010006195 arginyl-glycyl-aspartyl-cysteine Proteins 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000002601 intratumoral effect Effects 0.000 abstract description 5
- 239000011148 porous material Substances 0.000 abstract description 5
- 230000005855 radiation Effects 0.000 abstract description 4
- -1 sonosensitizers Substances 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 108091006146 Channels Proteins 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 75
- 229950008737 vadimezan Drugs 0.000 description 40
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 37
- 238000000338 in vitro Methods 0.000 description 25
- 230000008499 blood brain barrier function Effects 0.000 description 23
- 210000001218 blood-brain barrier Anatomy 0.000 description 23
- 239000013474 COF-1 Substances 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000000274 microglia Anatomy 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108010064942 Angiopep-2 Proteins 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 229960005540 iRGD Drugs 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- 238000000527 sonication Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 208000032612 Glial tumor Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 230000005975 antitumor immune response Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 239000000568 immunological adjuvant Substances 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 229940020947 fluorescein sodium Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000011056 performance test Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002336 repolarization Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000012651 immune agonist Substances 0.000 description 3
- 229940044680 immune agonist Drugs 0.000 description 3
- 230000001571 immunoadjuvant effect Effects 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FYGHSUNMUKGBRK-UHFFFAOYSA-N 1,2,3-trimethylbenzene Chemical compound CC1=CC=CC(C)=C1C FYGHSUNMUKGBRK-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001694 thigh bone Anatomy 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- DUCCKQSNXPFEGT-UHFFFAOYSA-N 4-hydroxy-5-[(2-hydroxyphenyl)methylideneamino]naphthalene-2,7-disulfonic acid Chemical compound Oc1ccccc1C=Nc1cc(cc2cc(cc(O)c12)S(O)(=O)=O)S(O)(=O)=O DUCCKQSNXPFEGT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-BJUDXGSMSA-N Boron-10 Chemical compound [10B] ZOXJGFHDIHLPTG-BJUDXGSMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000037449 immunogenic cell death Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002055 nanoplate Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000009203 neutron therapy Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000013384 organic framework Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
A multifunctional boron-rich nano targeting preparation based on a covalent organic framework material, a preparation method and application thereof belong to the technical field of medicines. The multifunctional boron-rich nano targeting preparation is used as an excellent boron nano medicament through a boron-rich covalent organic framework material COF, and realizes high-efficiency load on immune adjuvants, photosensitizers, sonosensitizers, chemotherapeutic drugs and the like due to unique high specific surface area, pi-pi stacking and pore channel interaction; DSPE-PEG by surface modification2k-X molecules cross the barrier, enabling intratumoral implementation10B. Co-delivery of drug molecules and photosensitizers. The multifunctional boron-rich nano targeting preparation observes the distribution condition of the drug in cells through a fluorescence microscope, and monitors the distribution in the nano-sheet body in real time so as to establish the optimal neutron irradiation condition; intratumoral delivery by simultaneous delivery10B and the drug molecules realize the targeted radiation and immune combined treatment of BNCT.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a multifunctional boron-rich nano targeting preparation based on a covalent organic framework material, and a preparation method and application thereof.
Background
Brain gliomas are the most common primary craniocerebral tumors arising from brain and spinal glioblastomas canceration. The characteristics of strong transferability, high infiltration, strong drug resistance and the like cause that the recurrence rate and the fatality rate are higher. The annual incidence rate of brain glioma in China is reported to be 5-8/10 ten thousand people, and the 5-year fatality rate is ranked 3 rd in the whole tumor, and is only second to pancreatic cancer and lung cancer. The traditional treatment modalities mainly include surgical resection, radiation therapy and chemotherapy. However, the development process of brain glioma is accompanied by the problems of tumor cell diffusion infiltration, unclear infiltration boundary and the like, and the brain glioma is difficult to completely remove by an operation. Radiotherapy is limited by the radiation dose of the brain and is easily tolerated, resulting in poor therapeutic effect. In addition, the blood-brain barrier (BBB) in the brain limits the enrichment of over 95% of small-molecule drugs and biological macromolecules into brain tissue, making drug therapy difficult to achieve. Therefore, the development of a high-efficiency and low-toxicity treatment strategy for the brain glioma is of great significance.
A novel Boron Neutron Capture Therapy (BNCT) as a noninvasive tumor treatment method is a binary chemoradiotherapy with strong targeting property and high energy transmission linear density in a cell scale and has strong tissue penetrationHigh permeability, high controllability, short treatment time and the like. The principle of action is the stable isotope boron 10: (10B) Upon irradiation with low-energy (0.025 eV) or epithermal neutrons (10,000 eV) a neutron capture-fission reaction occurs, followed by instability11B isotope undergoes nuclear fission reaction to produce high-energy and short-range alpha particles (4He2+) And7Li3+the particles further exert a tumor cell killing effect. Alpha particles and7Li3+the range of the particles is respectively 10 mu m and 5 mu m, the particles are limited within the target cell scale (20 mu m), the influence on non-target cells is small, and the damage is low. It is worth mentioning that BNCT provides a valuable solution for deep tumor therapy since high energy neutron beams can penetrate thick tissues and bones.
Advantages of BNCT treatment also include:the generated alpha rays can kill tumor cells in the division stage and the stationary stage at the same time (the traditional radiotherapy and chemotherapy mainly act on cells with vigorous division and are insensitive to the tumor cells in the stationary stage);the tumor cells in an anaerobic state can be killed at the same time without additional oxygenation (the traditional radiotherapy has low treatment sensitivity on the anaerobic cells);the generated lethal injury and potential lethal injury can not be subjected to DNA repair, and the composition has obvious curative effect on refractory tumors capable of repairing DNA injury after chemotherapy and radiotherapy and can effectively inhibit tumor recurrence.
Studies have shown that tumor cells often use multiple mechanisms to escape immune surveillance, and a single therapeutic strategy is often difficult to effectively overcome tumor metastasis. Although physical therapies such as BNCT can trigger immunogenic cell death to a certain extent, the anti-tumor immune response generated by radiotherapy-induced organisms is not enough to effectively prevent tumors from developing metastases to the far end. Therefore, the combined application of radiotherapy and immunotherapy provides a new idea for tumor treatment, namely, the combined application of radiotherapy and immunotherapy activates an organism to generate anti-tumor immune response while killing in-situ solid tumors, blocks tumor immune escape, breaks through immune suppression caused by tumors, exerts the optimal anti-tumor effect and finally prevents tumor recurrence. DMXAA (2, 5-pentoxifylline, Vadimezan) is an agonist of the interferon gene stimulating factor (STING) expressed in antigen presenting cells. DMXAA binds to STING proteins on the endoplasmic reticulum of dendritic cells, stimulates dendritic cell maturation and antigen presentation. In the tumor immunotherapy, the compound can be used as an immune agonist to start the anti-tumor immune response of the body.
Currently, treatment of brain gliomas by BNCT is not fully generalized, primarily due to the limited ability of current boron delivery agents to enrich for brain gliomas. In order to improve the treatment effect of BNCT on brain glioma, the problem of solving the intracerebral delivery of boron atoms becomes a crucial issue. Nanocarriers have the advantage of being unique as boron delivery agents. On one hand, the nano-carrier can improve the water solubility of the medicine, realize intravenous injection, enhance the curative effect of the medicine and reduce the toxic and side effect; on the other hand, the natural tumor passive targeting characteristic and the surface-modifiable active targeting characteristic of the nano-carrier are utilized to realize crossing the blood brain barrier and specific accumulation in brain glioma cells.
At present, the covalent organic framework structure bonded by boron-oxygen bonds is used as a nano boron-rich drug combined delivery immune agonist and a fluorescent probe to realize the combined treatment of BNCT and immunotherapy, and is not reported at home and abroad.
Disclosure of Invention
The invention aims to provide a tumor-targeted multifunctional boron-rich nano-drug to realize10The high-efficiency delivery of the B atom and the activation of anti-tumor immune response are applied to BNCT-immune combination treatment, and the targeting of different types of tumors can be realized by replacing different targeting peptides. The boron-rich covalent organic framework which modifies the targeting molecule and simultaneously loads the immune agonist and the fluorescent probe is self-assembled into the multifunctional boron-rich nano-drug, so that enough boron-rich nano-drug can be efficiently and safely transported10B to tumor cells, and simultaneously starting body specific immune response through the delivered immune adjuvant, and monitoring in tumors through fluorescent tracing and PET imaging10And (4) the content of B. The basic process is as follows: the targeting peptide modified on the surface of the nano preparation is used for crossing blood brain barrier and targeting tumor sites, and then the targeting peptide is used for targeting the tumor sites10B content is irradiated by neutron and radiotherapy is carried out. The carrier releases immunoadjuvant to activate Dendritic Cells (DCs) to mature and promote presentation of tumor associated antigens, and enhances CD8+ T cells infiltrate into the tumor area, inhibiting in situ tumor and tumor metastasis and recurrence. Multifunctional boron-rich nano targeting preparation realizes10The dual role of precise localization at the B atom targeting organ and cell level and activation of specific anti-tumor immune responses, thus enabling the innovative tumor treatment strategy of BNCT and immune combination.
The technical scheme adopted by the invention is as follows: the multifunctional boron-rich nano targeting preparation is a nano-drug suspension with the diameter of 80-180 nm, which is self-assembled by a boron-rich covalent organic framework material COF loaded with a drug and a photosensitizer and a targeting substance.
The boron-rich covalent organic framework material COF is synthesized by taking p-phenylboronic acid and (3-aminopropyl) -triethoxysilane as raw materials through a tube-sealing solvothermal method.
The medicine is selected from 2, 5-pentoxifylline (DMXAA), adriamycin (DOX) and Paclitaxel (PTX). DOX is a broad-spectrum antitumor drug, can inhibit the synthesis of RNA and DNA, and has effect on various tumors. Is suitable for malignant lymphoma, breast cancer, bronchogenic carcinoma, neuroblastoma, bladder cancer, thyroid cancer, prostatic cancer, head and neck squamous carcinoma, gastric cancer, and hepatocarcinoma. PTX is a natural anticancer drug that can destabilize the microtubules and tubulin dimers that make up microtubules from dynamic equilibrium, stabilize microtubules and inhibit the mitosis and trigger apoptosis of cancer cells, thereby effectively preventing the proliferation of cancer cells and playing a role in anticancer. Has been widely used for treating breast cancer, ovarian cancer, partial head and neck cancer and lung cancer in clinic.
The photosensitizer is selected from chlorin e6 (Ce 6) and IR780 dye.
The target comprises DSPE-PEG2k-X and DSPE-PEG2k,DSPE-PEG2k-X has the following structure:
wherein X is selected from the following structures:
each milliliter of the suspension contains 3-5 mg of boron-rich covalent organic framework material COF, and each milliliter of the suspension is loaded with 0.25-1 mg of photosensitizer, 0.5-2 mg of medicine and 1.2-12 mg of DSPE-PEG2k-X。
A preparation method of a multifunctional boron-rich nano-targeting preparation based on a covalent organic framework material comprises the following steps:
the preparation method comprises the following steps of taking terephthalic acid diborate (BDBA) and (3-aminopropyl) -triethoxysilane (APTES) as raw materials, taking 1,3, 5-trimethylbenzene and 1, 4-dioxane as solvents, synthesizing a boron-rich covalent organic framework material (COF) by a tube-sealed solvothermal method, and carrying out vacuum drying to obtain white solid powder.
Secondly, mixing the white solid powder obtained in the step with a DMSO solution in which a photosensitizer and a medicament are dissolved, carrying out ultrasonic oscillation, and adsorbing the medicament and the photosensitizer through a pore channel of the boron-rich covalent organic framework material COF and pi-pi action to obtain the massive boron-rich covalent organic framework material COF loaded with the medicament and the photosensitizer.
Step IIIAdding dissolved target (DSPE-PEG)2k-X and DSPE-PEG2k) Mixing the ethanol solution, and ultrasonically oscillating. Stripping the blocky boron-rich covalent organic framework material COF under the action of ultrasonic, and slowly adding deionized water to emulsify the blocky boron-rich covalent organic framework material COF.
Fourthly, the stepDialyzing the obtained drug-loaded nanosheet suspension in a phosphate buffer solution, sampling at intervals, passing through a sephadex chromatographic column, monitoring the position and number of peaks, and completing purification when only a single peak exists to obtain a nanometer drug suspension with the diameter of 80-180 nm, thus obtaining the multifunctional boron-rich nanometer targeting preparation.
The definitions of the medicine, the photosensitizer and the target substance are the same as those of the multifunctional boron-rich nano-targeting preparation.
The steps areThe method adopts a three-time freezing-pump-melting circulation method to remove the gas in the mixed solvent of mesitylene and 1, 4-dioxane, and comprises the following specific steps: freezing the solvent by using liquid ammonia, vacuumizing a sealed tube by using an oil pump, heating in a water bath to melt the solvent, releasing gas in the solvent, freezing the solvent by using liquid nitrogen again, and circulating for three times. The prepared boron-rich covalent organic framework material COF is dried into white solid powder by vacuum, and is prepared from terephthalic acid diboronic acid and (C)The molar ratio of the 3-aminopropyl) -triethoxysilane is 1: 3-4.5, and the volume ratio of the trimethylbenzene to the 1, 4-dioxane is 1: 1-1.5.
The steps areThe mass ratio of the traditional Chinese medicine, the photosensitizer and the boron-rich covalent organic framework material COF is 1-4: 2-8: 12-20, and ultrasonic oscillation is carried out for 15-30 min. Preferably, the mass ratio of the medicine to the photosensitizer to the boron-rich covalent organic framework material COF is 2-4: 2-5: 15-20, most preferably, the mass ratio of the medicine to the photosensitizer to the boron-rich covalent organic framework material COF is 2: 1: 10.
the steps areThe mass ratio of the middle target to the boron-rich covalent organic framework material COF (chip on film) is 3: 1-5: 1, and the DSPE-PEG (polyethylene glycol) is2kThe mass fraction of X in the target substance is 10-90%, and the ethanol solution of the target substance is dispersed in the stepIn the obtained solution, stripping is carried out under the action of ultrasound, and a boron-rich covalent organic framework material COF loaded with a medicament and a photosensitizer and a target are self-assembled to form a suspension.
The steps areThe adding speed of the deionized water in the ultrasonic emulsification process is 20 uL/min.
The multifunctional boron-rich nano targeting preparation based on the covalent organic framework material is used for preparing anti-tumor drugs.
The tumor comprises brain glioma, breast cancer, ovarian cancer, liver cancer, kidney cancer, lung cancer, colon cancer, bladder cancer, pancreatic cancer, uterine cancer, stomach cancer and rectal cancer.
The boron-rich covalent organic framework material COF is a planar network structure which is synthesized by taking p-phenylboronic acid (BDBA) as a raw material and taking 3-aminopropyl) -triethoxysilane (APTES) as a stabilizer through a tube-sealing solvothermal method, is connected by rigid building units and is stacked through the action of pi-pi between layers. As a boron nano-drug for BNCT, the boron-containing nano-drug has high boron content and extremely low cytotoxicity to normal cells. The boron-rich covalent organic framework material COF can adsorb various hydrophobic and aromatic molecular drugs (such as photosensitizer, sonosensitizer, immunologic adjuvant and the like) through pi-pi conjugated or porous channels. After the fluorescent probe is stably adsorbed, the in-vivo tracing of the boron nano-drug and the determination of the intratumoral peak reaching time are facilitated. The stable adsorbed molecular medicine such as immunologic adjuvant can induce body specific anti-tumor immune response.
DSPE-PEG2kThe amphiphilic polymer is composed of phospholipid and polyethylene glycol 2000, has the characteristics of biocompatibility and biosafety, is widely applied to drug delivery, gene transfection and vaccine delivery, and can obviously improve the circulation time in vivo and stably encapsulate drugs. The end of PEG can be connected with an active group (such as maleimide and-Mal) for coupling antibody and polypeptide to realize targeted drug delivery. Boron-rich covalent organic framework material COF and DSPE-PEG2k-X and DSPE-PEG2kSelf-assembly process: amphiphilic block polymer DSPE-PEG with hydrophilic group and hydrophobic group2kAnd DSPE-PEG2k-dissolving X in an organic solvent, by primary sonication, to obtain DSPE-PEG2kAnd DSPE-PEG2kWrapping the surface and the pore canal of the boron-rich covalent organic framework with-X, and then slowly dripping deionized water, DSPE-PEG under the ultrasonic action2kAnd DSPE-PEG2kThe hydrophilic end of the-X is dispersed in the water phase, and the hydrophobic end is closely attached to the surface of the boron-rich covalent organic framework of the hydrophobic inner core and the pore channel to form the nano suspension with good dispersibility.
The DSPE-PEG2kX is via distearoylphosphatidylethanolamine-maleimide polyethylene glycol 2000 (DSPE-PEG)2k-Mal) polyethylene glycol terminated maleimide (-Mal) and low density lipoproteinThe protein is obtained by coupling reaction of a white receptor related protein Angiopep-2, tumor cell-penetrating peptides HS-TAT, HS-iRGD, HS-RGD or sulfydryl (-SH) on a tumor neovascular endothelial cell targeting peptide HS-NGR, and the specific synthesis steps are as follows: 3 equivalents of DSPE-PEG2kmixing-Mal and 1 equivalent of Angiopep-2, HS-TAT, HS-iRGD, HS-RGD or HS-NGR, adding PBS, stirring in dark at room temperature for 10-12 hours, dialyzing in ice water bath for 3 hours, changing liquid for 1 time per hour, removing PBS, and freeze-drying to obtain solid powder DSPE-PEG2k-X. The polypeptide can be obtained by Hangzhou Zhongji peptide biochemistry Co Ltd, and has the following structure:
HS-TAT:Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-SH;
HS-iRGD:Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-SH;
HS-RGD:Arg-Gly-Asp-Cys-SH;
HS-NRG:Cys-Asn-Gly-Arg-Val-Ser-Thr-Asn-Gly-Arg-Cys-SH;
angiopep-2 (24 KDa) is a novel polypeptide consisting of 19 amino acid molecules that can be endocytosed into brain tumors mediated by low density lipoprotein receptor-related protein (LRP) expressed on the BBB. Research shows that human glioma cells and mouse glioma cells both express LRP receptor and have application prospect of clinical transformation.
DSPE-PEG modified with targeting molecule Angiopep-22kThe specific preparation method of-X is as follows: 3mg of distearoylphosphatidylethanolamine-maleimide polyethylene glycol 2000 (DSPE-PEG)2k-Mal) and 1mg of Angiopep-2, adding 5mL of phosphate buffer (pH 7.4), and stirring at room temperature in the dark for 12 hours to allow coupling reaction between thiol (-SH) of Angiopep-2 and maleimide (Mal-) at the end of polyethylene glycol. 2, 4, 6, 8, 10 and 12 hours of reaction solution is taken to react with Ellman's reagent analysis solution, and the OD value at 412 nm is measured to monitor the reaction. Experiments prove that the reaction is basically complete after 12 hours of reaction, the solution is dialyzed for 3 hours in ice water bath, the solution is changed for 1 time per hour, and the white solid powder DSPE-PEG is obtained by freeze drying2k-Ang, and storing at-20 ℃ for later use.
The multifunctional boron-rich nano targeting preparation comprisesCarrier module, medicated module, targeting module. By DSPE-PEG in the target2k-X enables targeting to specific tumor cells or lesions, simultaneously enabling co-delivery of drug molecules and photosensitizers, visualization tracking by photosensitizers, and innovative tumor treatment strategies with combination of chemotherapy and radiotherapy by drug molecules. For example: boron-rich covalent organic framework material COF loaded with immunological adjuvant DMXAA and photosensitizer Ce6 and targeting agent (DSPE-PEG)2k-Ang and DSPE-PEG2k) The self-assembled multifunctional boron-rich nano targeting preparation realizes the effect of the brain glioma internal section by the Blood Brain Barrier (BBB) crossing of the Angiopep-2 molecule modified by the nano preparation10B. Co-delivery of the immunoadjuvant DMXAA and the imaging molecule Ce 6. The fluorescence imaging capability of the Ce6 molecule can realize in-vivo tracing of the nanosheets, and meanwhile, the aza-ring structure of the Ce6 molecule can be effectively combined with that of the Ce6 molecule64Cu2+Chelation, realizing in vivo Positron Emission Computed Tomography (PET) imaging, and monitoring in vivo distribution of the nanosheets in real time to formulate optimal neutron irradiation conditions. The co-delivered immunological adjuvant DMXAA can be combined with STING protein on endoplasmic reticulum of DCs, release Interferon-beta (Interferon-beta, INF-beta), promote maturation of DCs cells, promote presentation of tumor-associated antigens, and enhance infiltration of Cytotoxic T Lymphocytes (CTL) to tumor regions, thereby killing tumor cells.
The invention has the beneficial effects that: the multifunctional boron-rich nano targeting preparation based on the covalent organic framework material is prepared by self-assembling a boron-rich covalent organic framework material COF loaded with a medicament and a photosensitizer and a target, and the boron-rich covalent organic framework material COF is formed by connecting organic construction elements through dynamic covalent bonds and has a periodic two-dimensional (2D) or three-dimensional (3D) network structure, so that the multifunctional boron-rich nano targeting preparation has the characteristics of large specific surface area, small density, high porosity, good stability, uniform pore diameter, adjustable structure, diversified functions and the like. The covalent organic framework bonded by the boron-oxygen bond after being modified by adding the stabilizer contains abundant boron atoms, and can be used as an excellent boron nano-drug. In addition, due to their unique high specific surface area, pi-pi stacking and channel interactionsThe valuable organic framework has very high loading and encapsulating capacity on hydrophobic drugs and aromatic drugs, and has unique advantages and potential application values in the aspects of high-efficiency loading and delivery of immunoadjuvants, photosensitizers, sonosensitizers, chemotherapeutic drugs and the like. The multifunctional boron-rich nano targeting preparation is prepared by surface modification of DSPE-PEG2k-X molecules cross the barrier, enabling intratumoral implementation10B. Co-delivery of drug molecules and photosensitizers. Observing the distribution condition of the drug in the cell through a fluorescence microscope, and monitoring the distribution in the nanosheet body in real time so as to establish the optimal neutron irradiation condition; intratumoral delivery by simultaneous delivery10B and the drug molecules realize the targeted radiation and immune combined treatment of BNCT.
In conclusion, the multifunctional boron-rich nano targeting preparation has clear advantages and wide application prospect, realizes BNCT and immune combined treatment, activates specific anti-tumor immune response while killing tumor cells, plays a synergistic anti-cancer role, has good targeting property and small toxic and side effects, and lays a foundation for thoroughly treating tumors.
Drawings
FIGS. 1A-1E are characterization plots of multifunctional boron-rich nano-targeting formulation DM & Ce6@ COF-Ang 1.
Wherein (a) is DSPE-PEG2k-graph of reaction rates for Mal and Angiopep-2;
(b) is a powder X-ray diffraction (PXRD) characterization chart of APTES-COF-1;
(c) a purification analysis chart of DM & Ce6@ COF-Ang 1;
(d) thermogravimetric analysis chart of DM & Ce6@ COF-Ang 1;
(e) is an ultraviolet-visible absorption spectrum of DM & Ce6@ COF-Ang 1;
(f) fluorescence spectrum for DM & Ce6@ COF-Ang 1;
(g) is an ultraviolet lamp diagram of the boron-rich nano preparation;
(h) is an infrared spectrum of DM & Ce6@ COF-Ang 1;
(i) XPS energy level diagram for DM & Ce6@ COF-Ang 1;
(j) the B, C, N, O element distribution diagram for DM & Ce6@ COF-Ang 1.
FIG. 2 is a diagram for investigating the appearance and stability of the multifunctional boron-rich nano preparation.
(a) TEM image of DM & Ce6@ COF-Ang 1;
(b) AFM images of DM & Ce6@ COF-Ang 1;
(c) is a particle size change diagram of the nano preparation in water for 48 hours;
(d) a 7-day stability survey chart of DM & Ce6@ COF-Ang1 in water;
(e) a 7-day stability profile for DM & Ce6@ COF-Ang1 in different concentrations of Fetal Bovine Serum (FBS);
(f) is zeta potential diagram of nano preparation in water.
FIGS. 3A-3C are graphs showing the results of in vitro cell uptake experiments for multifunctional boron-rich nano-formulations.
Wherein (a) is an uptake graph of the boron-rich nano preparation by a fluorescence microscope monitoring cell;
(b) is a quantitative analysis chart of the cell uptake of the boron-rich nano preparation;
(c) evaluating the toxicity graph of the boron-rich nano preparation on the bEND.3 cells and the GL261 cells by an MTT method;
(d) detection of uptake patterns of cells to nanoplates for ICP-OES
(e) Is the distribution map of the boron-rich nano preparation in the organelle;
(f) intracellular profiles of DM & Ce6@ COF-Ang1 were monitored for fluorescence microscopy.
FIG. 4 is a diagram of the construction and evaluation of an in vitro blood-brain barrier model.
(a) Is an in vitro blood brain barrier model leakage test chart;
(b) is an in vitro blood brain barrier model fluorescein sodium penetration experimental diagram;
(c) an attempt was made to evaluate the ability of boron-rich nanoformulations to cross the blood brain barrier in vitro.
FIGS. 5A-5D are graphs of the effect of boron-rich nanoformulations on immune cells in vitro.
(a) Activation map of dendritic cells (BMDCs) derived from bone marrow in vitro;
(b) activation and repolarization patterns for in vitro bone marrow derived macrophages (M phi);
(c) an identification map of primary cultured Microglia cells (Microglia) in vitro;
(d) activation and repolarization profiles for primary cultured Microglia cells (Microglia) in vitro.
FIG. 6 is a diagram of in situ model evaluation of mouse brain glioma using boron-rich nano-formulation.
(a) Analyzing maps for in vivo imaging
(b) Is a boron content tissue distribution map;
(c) DMXAA content profile in brain gliomas was determined for HPLC.
The invention is described in detail below with reference to specific embodiments. The scope of the present invention is not limited to the specific embodiments but is defined by the scope of the claims.
Detailed Description
Example 1
Preparation of amino functionalized covalent organic framework material-1 (APTES-COF-1):
the APTES-COF-1 is prepared by the following steps which are shown as the formula (I):
(I)
1) 0.165 g of 1, 4-terephthalocycloic acid (BDBA) and 0.05 g of (3-aminopropyl) -triethoxysilane (APTES) were mixed in 5mL of a mixed solution of mesitylene and 1, 4-dioxane in a volume ratio of 1:1 under a dry nitrogen atmosphere.
2) The reactants are treated by ultrasonic (40 KHz, 100W) for 60 min, then vacuumized, heated to 75 ℃ and reacted for 20 h.
3) After the reaction, the reaction mixture was repeatedly washed with acetone and filtered to obtain a white powder, which was dried under vacuum at 120 ℃ and stored at room temperature for further use.
Example 2
Preparation of amino functionalized covalent organic framework material-2 (APTES-COF-2):
1) 0.165 g of 1, 4-terephthalocycloic acid (BDBA) and 0.08 g of (3-aminopropyl) -triethoxysilane (APTES) were mixed in 5mL of a mixed solution of mesitylene and 1, 4-dioxane in a volume ratio of 1:1.25 under a dry nitrogen atmosphere.
2) The reactants are treated by ultrasonic (40 KHz, 100W) for 60 min, then vacuumized, heated to 75 ℃ and reacted for 20 h.
3) After the reaction, the reaction mixture was repeatedly washed with acetone and filtered to obtain a white powder, which was dried under vacuum at 120 ℃ and stored at room temperature for further use.
Example 3
Preparation of amino functionalized covalent organic framework material-3 (APTES-COF-3):
1) 0.165 g of 1, 4-terephthalocycloic acid (BDBA) and 0.10 g of (3-aminopropyl) -triethoxysilane (APTES) were mixed in 5ml of a mixed solution of mesitylene and 1, 4-dioxane in a volume ratio of 1:1.5 under a dry nitrogen atmosphere.
2) The reactants are treated by ultrasonic (40 KHz, 100W) for 60 min, then vacuumized, heated to 75 ℃ and reacted for 20 h.
3) After the reaction, the reaction mixture was repeatedly washed with acetone and filtered to obtain a white powder, which was dried under vacuum at 120 ℃ and stored at room temperature for further use.
Example 4
DSPE-PEG2KPreparation of Ang:
DSPE-PEG for modifying targeting molecules2K-Ang is by DSPE-PEG2K-Mal-terminated maleimide and Angiopep-2-terminated thiol (-SH) in buffer. The method comprises the following specific steps:
1) 3mg of distearoylphosphatidylethanolamine-maleimide polyethylene glycol 2000 (DSPE-PEG)2kMal) and 1mg Angiopep-2, 5mL Phosphate Buffered Saline (PBS) was added, and stirred at room temperature for 12 h in the dark.
2) Taking reaction liquid of 2, 4, 6, 8, 10 and 12 hours to react with Ellman's reagent analysis liquid respectively, and measuring OD value at 412 nm to monitor the reaction progress.
3) Preparing Angiopep-2 solution (0.2 mg/mL) with the same concentration, measuring the ultraviolet absorption at 412 nm of the two solutions under an ultraviolet spectrophotometer after reacting with Ellman's reagent, and calculating the yield according to the following formula:
yield% = (OD)Ang-SH-ODAng-PEG-DSPE)/(ODAng-SH-ODBlank)×100%
Wherein ODAng-SH、ODAng-PEG-DSPE、ODBlankRespectively, the ultraviolet absorption at 412 nm after the reaction of Ang-SH, Ang-PEG-DSPE and a blank solvent with Ellman's reagent.
4) As shown in FIG. 1(a), the reaction rate reached 92.5% in 12 hours, the solution was dialyzed for 3 hours in an ice-water bath, and the solution was changed 1 time per hour, and freeze-dried to obtain a white solid powder, which was stored at-20 ℃ for further use.
Example 5
By replacing Angiopep-2 with HS-TAT, HS-iRGD, HS-RGD or HS-NGR, DSPE-PEG was prepared according to the method of example 42K-TAT、DSPE-PEG2K-iRGD、DSPE-PEG2K-RGD、DSPE-PEG2KThe raw materials HS-TAT, HS-iRGD, HS-RGD and HS-NGR are purchased from Hangzhou Zhongji peptide Biochemical Co.
Example 6
Preparation of multifunctional boron-rich nano-targeting preparation DM & Ce6@ COF-Ang 1:
the multifunctional boron-rich nano targeting preparation is prepared according to the following steps, wherein the adopted blocky COF-1 is prepared in the first embodiment. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 20 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 2mg DSPE-PEG 2k200 μ L of ethanol from Ang, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) Purification by dialysis gave a suspension, DM & Ce6@ COF-Ang1
In addition, the same method is adopted to remove DMXAA, Ce6 and DSPE-PEG in the prescription2kThe Ang component is prepared into a targeting group DM @ COF-Ang (Ce 6 is removed) and a non-targeting group DM respectively&Ce6@ COF (removal of target), DM @ COF (removal of target)Except for the target and Ce 6) and COF (except for DMXAA, target and Ce 6).
Example 7
Preparation of multifunctional boron-rich nano-targeting preparation DM & Ce6@ COF-Ang 2:
the multifunctional boron-rich nano-targeting preparation DM & Ce6@ COF-Ang2 is prepared by adopting the bulk COF-1 in the first embodiment, and the preparation steps of the multifunctional boron-rich nano-targeting preparation are as follows:
1) mu.L of DMXAA (15 mg/mL) and 20. mu.L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 3mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 12mg2kAnd 3mg DSPE-PEG 2k200 μ L of ethanol from Ang, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-Ang 2.
Example 8
Preparation of multifunctional boron-rich nano-targeting preparation DM & Ce6@ COF-Ang 3:
a multifunctional boron-rich nano-targeting preparation DM & Ce6@ COF-Ang3 was prepared using the bulk COF-1 prepared in example one. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 30 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 4 mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of 14 mg DSPE-MPEG2kAnd 1mg DSPE-PEG 2k200 μ L of ethanol from Ang, shaking for 30 min.
3) 700 μ L of deionized water (20 μ L/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-Ang 3.
Example 9
Preparation of multifunctional boron-rich nano targeting preparation DOX & Ce6@ COF-Ang:
a multifunctional boron-rich nano-targeting formulation DOX & Ce6@ COF-Ang was prepared using the bulk COF-2 of example two. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) mu.L DOX (20 mg/mL) and 40. mu.L Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-2 and sonicated for 20 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 2mg DSPE-PEG 2k200 μ L of ethanol from Ang, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) Purification by dialysis gave a suspension, DOX & Ce6@ COF-Ang was obtained.
Example 10
Preparation of multifunctional boron-rich nano targeting preparation DM & IR780@ COF-Ang:
a multifunctional boron-rich nano-targeting formulation DM & IR780@ COF-Ang was prepared using the bulk COF-3 of example III. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 25mL of IR780 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-3 and sonicated for 25 min.
2) Adding a mixture of 14 mg DSPE-MPEG2kAnd 1mg DSPE-PEG 2k200 μ L of ethanol from Ang, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & IR780@ COF-Ang.
Example 11
Preparation of multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-TAT:
a multifunctional boron-rich nano-targeting formulation DM & Ce6@ COF-TAT was prepared using the bulk COF-1 of example one. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 35 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 2mg DSPE-PEG 2k200 μ L ethanol of TAT, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-TAT.
Example 12
Preparation of multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-iRGD:
the multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-iRGD is prepared by adopting the bulk COF-1 of the first embodiment. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 40 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 2mg DSPE-PEG 2k200 μ L ethanol with iRGD, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-iRGD.
Example 13
Preparing a multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-RGD:
the multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-RGD is prepared by adopting the bulk COF-1 of the first embodiment. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 45 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 2mg DSPE-PEG 2k200 μ L of ethanol with RGD, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-RGD.
Example 14
Preparation of multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-NGR:
a multifunctional boron-rich nano-targeting formulation DM & Ce6@ COF-NGR was prepared using the bulk COF-1 of example one. The preparation method of the specific multifunctional boron-rich nano targeting preparation comprises the following steps:
1) 50 μ L of DMXAA (15 mg/mL) and 30 μ L of Ce6 (20 mg/mL) in DMSO was added to a centrifuge tube containing 5mg of bulk COF-1 and sonicated for 15 min.
2) Adding a mixture of DSPE-MPEG containing 13 mg2kAnd 3mg DSPE-PEG 2k200. mu.L of ethanol from NGR, shaking for 30 min.
3) 700 μ L of deionized water (20 uL/min) was slowly added under sonication (40 KHz, 200W), and the emulsion was ultrasonically stripped.
4) The suspension was purified by dialysis to obtain DM & Ce6@ COF-NGR.
Example 15
The amino functionalized covalent organic framework material-1 (APTES-COF-1) and the multifunctional boron-rich nano targeting preparation prepared in the examples 1 and 6 are characterized:
(1) performance test experiment 1: the APTES-COF-1 is characterized by X-ray diffraction (PXRD) by an X-ray diffractometer (SmartLab 9kw, Japan) as shown in figure 1(b), and the result shows that the characteristic peak is consistent with the literature report, and the APTES-COF-1 is successfully synthesized.
(2) Performance test experiment 2: purification and thermogravimetric analysis of DM & Ce6@ COF-Ang1
A sephadex chromatographic column method is adopted to verify whether the free medicine can be completely removed by dialysis. As shown in fig. 1(c), the results indicate that purified boron-rich nanoformulations can be obtained after dialysis. The dialyzed and purified nano preparation is subjected to freeze drying and thermogravimetric analysis (Mettler Switzerland, SDTA851 e), the temperature rise range is 50-500 ℃, the temperature rise speed is 10 ℃/min, and as shown in (d) in figure 1, the result shows that the mass fraction of the covalent organic framework accounts for 25% of the whole nano material.
(3) Performance test experiment 3: ultraviolet and fluorescence spectrometry of DM & Ce6@ COF-Ang1
A3 ml quartz cuvette was charged with a DM & Ce6@ COF-Ang1 sample solution dispersed in water and the absorption curve of the sample was measured with a UV-visible spectrophotometer (Perkinelmer, Lambda 750S). Fig. 1(e) illustrates that DMXAA and Ce6 were successfully loaded simultaneously. The 1 mLDM & Ce6@ COF-Ang1 sample solution was added to a quartz cuvette and the emission curve (Ex: 345 nm) of the sample was tested using a fluorescence spectrometer (Hitachi, F7000) and, as shown in FIG. 1(F), both DMXAA and Ce6 were successfully loaded. FIG. 1(g) shows a fluorescent photograph under UV irradiation (365 nm).
(4) Performance test experiment 4: infrared spectrum of multifunctional boron-rich nano targeting preparation DM & Ce6@ COF-Ang1
The functional groups of the multifunctional boron-rich nano-targeting agent DM & Ce6@ COF-Ang1 were analyzed using Fourier transform Infrared Spectroscopy (FTIR, Thermo Fisher 6700), as shown in FIG. 1 (h). The FTIR spectrum shows that DMXAA and Ce6 are simultaneously supported on the boron-rich covalent organic framework material COF-1.
(5) Performance test experiment 5: elemental analysis of DM & Ce6@ COF-Ang1
The elements of the multifunctional boron-rich nano-targeting agent DM & Ce6@ COF-Ang1 were analyzed by X-ray photoelectron spectroscopy (XPS, Thermo Fisher), as shown in FIG. 1 (i). Mapping analysis was performed using high resolution transmission electron microscopy for the elemental composition of DM & Ce6@ COF-Ang1, as shown in FIG. 1 (j). Elemental analysis indicated that DM & Ce6@ COF-Ang1 is rich in a sufficient number of boron atoms.
Example 16
The multifunctional boron-rich nano-targeting formulation prepared in example 6 and the non-targeting set of DM & Ce6@ COF, DM @ COF, and COF nano-formulations were subjected to morphology and stability studies:
TEM images of functional boron-rich nano-targeting agent DM & Ce6@ COF-Ang1 were obtained by transmission electron microscopy (TEM, HT7700 EXALENS), as shown in FIG. 2(a), with a diameter of about 161 nm. The DM & Ce6@ COF-Ang1 was diluted 20-fold with deionized water, dispersed on a clean silicon wafer, dried and measured for thickness by atomic force microscopy (Brooks, Dimension Icon), as shown in FIG. 2(b), to be about 5 nm thick. A dynamic light scattering particle size plot of DM & Ce6@ COF-Ang1 dispersed in liquid for 48 h was obtained from 1mL of DM & Ce6@ COF-Ang1 solution by a Zeta potential and particle size analyzer (Malvern Zetasizer, Nanozs90), as shown in FIG. 2(c), with a particle size of about 171.4 nm in water, about 162.5 nm in PBS, and about 160.4 nm in 1640 complete medium. DLS tests after 48 h show that COF, DM @ COF, DM & Ce6@ COF, DM & Ce6@ COF-Ang1 have good stability. The particle size change of the nanosheets COF, DM @ COF, DM & Ce6@ COF and DM & Ce6@ COF-Ang1 in water within 7 days is measured by the same method, and as shown in figure 2(d), the boron-rich nano preparation is stable within 7 days. The particle size changes of the nanosheets COF, DM @ COF, DM & Ce6@ COF, DM & Ce6@ COF-Ang1 in different concentrations of FBS within 7 days are measured by the same method, and as shown in FIG. 2(e), the boron-rich nanoformulation is stable in different environments within 7 days. The potential test results are shown in FIG. 2(f), and the potential of DM & Ce6@ COF-Ang1 is about-15.3 mV.
Example 17
In vitro cell uptake experiments were performed on the multifunctional boron-rich nano-targeting formulation prepared in example 6 and the non-targeting set of DM & Ce6@ COF, DM @ COF, and COF nano-formulations
(1) Monitoring uptake of boron-rich nano-preparation by cells by fluorescence microscope
Selecting GL261 cells and bEND.3 cells with good growth state in logarithmic growth phase, digesting and collecting, adjusting cell density, and mixing 1mL cell suspension (3 × 10)5cell/mL) were evenly and slowly seeded in a 35 mm dish and cultured routinely for 12 h until the cells were adherent and fully expanded. Taking out the dish, removing supernatant, washing with PBS, and adding DM&Ce6@COF-Ang1、DM&Ce6@ COF, DM @ COF and COF nanoformulations, to a final concentration of 5. mu.g/mL Ce6, incubated for various periods of time in the absence of light. At 0.5 h, 1 h and 2h after the addition of the nano preparation, cells were taken out and the cell nuclei were labeled with DAPI. The fluorescence microscope observed the enrichment of Ce6, which was red fluorescent, in each group of cells, and an image was collected, as shown in fig. 3 (a). Quantitative analysis of fluorescence intensity As shown in FIG. 3(b), fluorescence imaging and analysis resultsIndicating that GL261 cells, bEND.3 cells, are paired with targeting group DM&The uptake of Ce6@ COF-Ang1 was significantly higher than that of the non-targeted group.
(2) MTT method for evaluating in vitro cytotoxicity of boron-rich nano preparation
Determination of DM by UV-Vis spectrophotometry&Ce6@COF-Ang1、DM&DMXAA content in Ce6@ COF, DM @ COF. Mouse brain microvascular endothelial cells (bEND.3) were plated in 96-well plates at 4X 10 per well3The density of individual cells was cultured at 37 ℃ for 24 hours. Thereafter, the medium was replaced with complete medium containing nanoformulations (0. mu.g/mL, 12.5. mu.g/mL, 25. mu.g/mL, 50. mu.g/mL, 75. mu.g/mL, 100. mu.g/mL) of different DMXAA concentrations. After 4 hours of incubation drug was withdrawn, fresh medium was added and incubated for 20 hours, after which the medium was discarded and 100 μ L of MTT was added to each well and further incubated for 4 hours. Subsequently, MTT (0.5 mg/mL) was replaced with 150. mu.L of dimethyl sulfoxide (DMSO), and the absorbance (OD) of each well was measured at 570 nm using a microplate reader, and an average of 6 duplicate wells was taken for each sample. The relative survival rate of the cells was calculated according to the following formula: (Experimental group OD)570Control group OD570) X 100%, the experiment was repeated 3 times. Toxicity of boron-rich nanopreparation on mouse glioma cells (GL 261) was determined in the same manner. As shown in fig. 3 (c), it can be seen that the drug is not significantly toxic to the b end.3 cells within a concentration range of 75 μ g/mL without neutron irradiation. The drug was not significantly toxic to GL261 cells at a concentration range of 100 μ g/mL in the absence of neutron irradiation.
(3) ICP-OES detection of uptake of nanosheet by cells
Collecting GL261 cells with logarithmic growth phase and good growth state, digesting, collecting and adjusting cell density, and mixing 1mL cell suspension (1 × 10)6cell/mL) were evenly and slowly seeded in six-well plates and cultured routinely for 12 h until the cells were adherent and fully expanded. The dishes were removed and the supernatant discarded, washed with PBS and 1mL of cell culture medium containing COF, DM @ COF, DMXAA @ COF-Ang1 nanosheets was added. After adding the nano-sheets for 0.5 h, 1 h, 2h and 4 h, removing supernatant, washing with PBS for three times, and collecting cells. 1mL of a solution containing 68% HNO3And 30% H2O2(V68% HNO3: V30% H2O2Digestion of the mixed solution of =3: 2), and measurement of the boron content in the cells by inductively coupled plasma emission spectroscopy (ICP-OES). As shown in FIG. 3(d), GL261 cells added with DM @ COF-Ang1 group reached a maximum concentration of 74.47. + -. 3.16 ppm at 2h, which is higher than the intracellular concentration required by BNCT10The B content was 20 ppm.
(4) Co-localization analysis of boron-rich nano preparation by monitoring cells with fluorescence microscope
Using free Ce6, DM&Ce6@ COF and DM&Ce6@ COF-Ang1 was incubated with GL261 cells for 2 hours, respectively, to explore the subcellular localization in GL261 cells. The distribution of several substances in GL261 cells was collected by confocal laser microscopy, as shown in FIG. 3(e), DM&Ce6@ COF-Ang1 mainly enters cells through a lysosomal pathway, and has high green fluorescence coincidence with LTG of the lysosomal probe, with a Pearson coefficient of 0.918. Free Ce6 and DM&The co-localization coefficients of Ce6@ COF with lysosomes were 0.758 and 0.625, respectively. And counting DM by using a fluorescence microscope&Intracellular distribution of Ce6@ COF-Ang1, shown in FIG. 3(f), 39.8% DM&The Ce6@ COF-Ang1 is distributed within a distance of 5 mu m from the nucleus, and is more favorable for alpha particles and7Li3+killing of the nucleus by the particle.
Example 18
Construction and identification of in vitro blood brain barrier model and evaluation of blood brain barrier crossing capability of multifunctional boron-rich nano targeting preparation
(1) Construction and leakage test of in vitro blood brain barrier model
The Transwell chamber was removed, DMEM medium was added and placed in a 24-well plate, and left to stand in a cell incubator for 20min for activation. bEND.3 cells in logarithmic growth phase at 1X 104 cell/well density was seeded in the upper Transwell chamber and 0.6 mL of medium was added to the 24-well plate in the lower Transwell chamber and placed in an incubator for 5 days until the cells were confluent (during which time the upper Transwell chamber cell medium was periodically changed to allow tight adherent growth of the bned.3 cells). mu.L and 200. mu.L of the medium were added to the upper and lower chambers of bEND.3, respectively, at a liquid level difference of 1 cm in the Transwell chamber, and the cells were placed in an incubator for further culture, and the record was made1.4 and 9 h, and observing whether the liquid level difference between the two chambers keeps the original height. As shown in fig. 4(a), the liquid level difference did not change significantly on day 5, i.e. the BBB in vitro modeling was initially judged to be successful.
(2) In vitro blood brain barrier model sodium fluorescein penetration experiment
Detecting BBB model in vitro culture by using fluorescein sodium (FLU), selecting bEND.3 independent culture model group and blank group, each group having 3 models, replacing whole solution with serum-free DMEM culture solution before measurement, adding 50 μ g/mL fluorescein sodium into the supply tank, placing at 37 deg.C and 0.5% CO2After culturing in an incubator for 5min, 10 min, 20min, 40 min and 80 min, 50 μ L of culture solution is taken from the receiving pool and the FLU amount passing through different models is measured by a fluorescence microplate reader. As shown in FIG. 4(b), the bEND.3 culture model group alone blocked the permeation of sodium fluorescein well.
(3) Evaluation of boron-rich Nanodiulation ability to cross the blood brain Barrier in vitro
And selecting a blood brain barrier model group qualified in a leakage test and a fluorescein sodium penetration test to evaluate the capability of free Ce6, DM & Ce6@ COF and DM & Ce6@ COF-Ang1 in crossing the blood brain barrier. Adding 300 mu L of solution of free Ce6, DM & Ce6@ COF and DM & Ce6@ COF-Ang1 (containing 10 mu g/mL Ce 6) into the donor pool, respectively, incubating for 3 h, and observing the uptake condition by using a fluorescence microscope, wherein the targeted group DM & Ce6@ COF-Ang1 has obvious capability of crossing the blood brain barrier as shown in FIG. 4 (c).
Example 19
The effect of the multifunctional boron-rich nano-targeting preparation prepared in example 6 on dendritic cells, macrophages and microglia induced and cultured in vitro was examined.
(1) Activation and maturation of bone marrow-derived dendritic cells (BMDCs)
Extraction and culture of BMDCs: after the mice are killed at the dislocated cervical vertebra, the mice are soaked in ethanol for disinfection, and the thighbones and the shinbones of the mice are dissected out and muscles attached to the thighbones and the shinbones are stripped. The femoral and tibial ends are carefully cut with scissors to expose the medullary cavity. The bone marrow contents were blown down with a 10 mL sterile syringe needle containing the culture medium. The cells were collected by centrifugation at 1800 rpm for 5 min. The isolated cells were cultured on sterile plates using LCM medium containing 20 ng/mL GM-CSF and 20 ng/mL IL-4. Fluid changes were made on days 3 and 6, and on day 7 for subsequent experiments.
Biomarker analysis of BMDCs: cells were incubated with free DMXAA, COF, DM @ COF-Ang, DMXAA + COF physically mixed groups (each group containing 25 μ g/mL DMXAA) at 37 ℃ for 4 hours, then stained with PE-Cy7-anti-mouse CD11c, PE-anti-mouse CD80, APC-anti-mouse CD86 at room temperature for 60 minutes, centrifuged and washed, then fixed with 1% PFA cell fixative at 4 ℃ for 90 minutes, and surface molecule expression was detected by flow cytometry, 20,000 cells were collected at a time, and data analysis was performed using FlowJo 9.0 software.
As shown in FIG. 5(a), DM @ COF-Ang has a significant activation effect on dendritic cells in vitro when the content of DMXAA is 25. mu.g/mL.
(2) Activation and repolarization of in vitro bone marrow derived macrophages (M phi)
Bone marrow-derived M phi cell induction: mouse bone marrow cells were collected using the procedure for extraction of BMDCs. The cells were cultured in 24-well plates at 37 ℃ for 6 days in LCM medium containing 20 ng/mL M-CSF, and supplemented with medium on day 3. Stimulating and culturing with IFN-gamma (100 ng/ml) and LPS (25 ng/ml) for 24 h at 7 days to induce M1 type macrophage; stimulation of culture with IL-4 (10 ng/ml) for 24 h induced M2-type macrophages.
Biomarker analysis of bone marrow-derived M phi cells: cells were incubated with free DMXAA, COF, DM @ COF-Ang, DMXAA + COF, respectively, for 48 hours at 37 ℃, then stained with PE-anti-mouse F4/80, PE-Cy7-anti-mouse CD206, APC-anti-mouse CD80 for 60 minutes at room temperature, centrifuged and washed, then fixed with 1% PFA cell fixative at 4 ℃ for 90 minutes, and surface molecule expression was detected by flow cytometry, 20,000 cells were collected each time, and data analysis was performed using FlowJo 9.0 software.
As shown in FIG. 5(b), DM @ COF-Ang has significant activation and repolarization effects on macrophages in vitro at DMXAA levels of 25. mu.g/mL.
(3) In vitro mouse primary Microglia (Microglia) culture and activation
1) Sterilizing clean mice in 24 h with 75% alcohol, cutting head under aseptic condition, cutting scalp and skull, taking out brain tissue, and placing in cold D-Hank's solution with pH of 7.2 and no calcium or magnesium.
2) Aseptically stripping brain tissue, removing cerebellum, separating cerebral cortex, and carefully stripping meninges and blood vessels.
3) Shearing the tissue to 1 mm by iris scissors3The left and right tissue blocks are digested by 0.125% trypsin, and are acted at 37 ℃ for 20min, and are shaken for 2-3 times in the process.
4) The supernatant was discarded and the complete inoculum added to stop digestion and rinsed twice. The pipette is gently blown and beaten until no obvious brain tissue lumps are observed by naked eyes, and the mixture is kept stand for 2 min.
5) The suspension was collected in a new centrifuge tube, centrifuged (1000 r/min, 10 min, 4 ℃) and the supernatant discarded. Adding complete culture solution for re-suspension, and filtering with a 200-mesh filter screen. 3 mice/dish were inoculated in 10 cm dishes.
6) Placing at 37 ℃ and 5% CO2The culture medium was changed once after 24 h in the incubator, and the solution was changed every 3d later, and the growth and survival of the cells were observed under a mirror.
7) And (3) culturing the cells for about 14-16 days, and observing the phenomenon of cell layering in the mixed glial cell culture under an inverted phase contrast microscope, namely the bottom layer is flat and provided with a plurality of raised astrocytes, and the microglia are obviously smaller and circular, have strong refractivity and are attached to the surfaces of the astrocytes to grow.
8) Pouring out the culture solution, digesting with 2-3 mL of 0.05% pancreatin, gently shaking the culture flask while observing, and transferring the digestion solution containing the floating microglia into a 10 mL centrifuge tube after the microglia attached to the astrocytes are separated, and immediately stopping digestion with the complete culture medium.
Microglia were seeded on slides in 24-well plates, stained by Hoechst
The cells marked with nuclei were substantially marked with the minigel marker CD11b, the positive rate of CD11b (CD11 b)+Hoechst+/Hoechst+) > 90%, as shown in FIG. 5 (c).
Surface marker molecule analysis of Microglia: cells were incubated with free DMXAA, COF, DM @ COF-Ang, DMXAA + COF physical mixed groups (each group was pulled with 25 μ g/mL DMXAA) for 48 hours at 37 ℃, then stained with PE-anti-mouse F4/80, PE-Cy7-anti-mouse CD206, APC-anti-mouse CD80 for 60 minutes at room temperature, after centrifugation and washing, fixed with 1% PFA cell fixative at 4 ℃ for 90 minutes, surface molecule expression was detected by flow cytometry, 20,000 cells were collected at a time, and data analysis was performed using FlowJo 9.0 software. As shown in FIG. 5(d), DMXAA @ COF-Ang exhibited significant activation and repolarization effects on Microglia in vitro at a DMXAA content of 25. mu.g/mL.
Example 20
In situ model evaluation of mouse brain glioma in situ model for multifunctional boron-rich nano targeting formulation DM & Ce6@ COF-Ang1 prepared in example 6 and non-target set DM & Ce6@ COF, DM @ COF and COF nano formulations
(1) Establishing glioma in-situ model
1) Cell preparation: selecting GL261 cell in logarithmic growth phase and good growth state for trypsinization, obtaining single cell suspension according to passage step, adjusting cell density to 4 × 107cell/mL, mixing the cell suspension evenly and placing the cell suspension in an incubator at 37 ℃ for later use;
2) anesthetizing the mice: 5 percent chloral hydrate is used for carrying out intraperitoneal injection anesthesia according to the weight (300 mg/kg) of the mouse, and the prone position of the mouse is fixed on a mouse brain stereotaxic apparatus after the anesthesia is successful;
3) mice were treated: the head of the mouse is unhaired and disinfected by iodophor, and the connection line of the inner canthus intersects with the sagittal midline of the head;
4) a longitudinal incision is 1 cm at the junction, a hydrogen peroxide cotton swab is used for wiping the surface of the skull, a bregma point is fully exposed, and a small hole with the diameter of 1 mm is drilled at a striatum part (0.6 mm in front of the bregma point and 1.8 mm on the right);
5) inoculation: sucking 5 μ L of glioma cell suspension with a micro-injector, vertically and slowly inserting needle 4.0 mm, then withdrawing needle 1.0 mm, staying for 5min, slowly injecting the cell suspension into mouse brain at uniform speed, standing for 5min, and slowly pulling out;
6) and (3) sewing: bone holes were closed with sterile bone wax, the mouse scalp was sutured with sterile thread, the mice were housed under normal conditions after iodine-containing sterilization, and 200 μ L ampicillin was injected subcutaneously for 3 consecutive days.
(2) In vivo imaging analysis
To further confirm the targeting effect and BBB crossing ability of DM & Ce6@ COF-Ang1, near infrared fluorescence imaging was performed on free Ce6, non-targeting set DM & Ce6@ COF, and targeting set DM & Ce6@ COF-Ang1 nanopreparations using In Vivo Imaging System (IVIS). As shown in fig. 6(a), Ce6 fluorescence of the tumor region DM & Ce6@ COF-Ang1 nano-formulation reached a maximum at 2 hours (circled in the figure), and in vitro imaging of tumors and other normal organs collected at 2 hours post-injection showed that the targeting group DM & Ce6@ COF-Ang1 nano-formulation had significant targeting effect and BBB crossing ability.
(3) Boron content texture distribution
When the tumor is 2 weeks, the tail vein of the tumor-bearing mice is injected with the DM of the target group&Ce6@ COF-Ang1 nanoformulation (50 mg/kg), mice were sacrificed 2h after injection. Rapidly extracting heart, liver, spleen, lung, kidney, brain and tumor tissue, and adding 5mL of the extract containing 68% HNO3And 30% H2O2(V68% HNO3: V30% H2O2Digestion of a mixed solution of =3: 2), determination of boron content by azomethine-H spectrophotometry, and treatment of DM @ COF group and PBS group were the same. As shown in FIG. 6(b), DM was injected&In tumors of the Ce6@ COF-Ang1 nano-preparation group10The content of B is 100.44 mug/g which is far higher than the treatment requirement of BNCT10B concentration (> 20. mu.g/g), and10the concentration ratio of B at the tumor site and the normal site (T: N = 6.9) is much larger than the required 3.
(4) HPLC determination of DMXAA content in brain glioma
When the tumor is 2 weeks, the tumor-bearing mice are injected with DM intravenously&Ce6@ COF-Ang1 nano-formulation (50 mg/kg), mice were sacrificed 2h after injection, tumor tissues were taken and homogenized with 1mL of deionized water. 100 μ L of the tissue homogenate was added to a tube containing 1mL of chromatographic grade methanol, sonicated for 1 h (40 KHz, 100W), and thenCentrifuge at 10000 rpm for 5 min. Taking supernatant obtained by centrifugation, and filtering with a 0.22 μm filter membrane; standard curves were prepared with 0.25, 0.5, 1, 2, 2.5. mu.g/mL standard solutions in chromatographic grade methanol. The mobile phase adopts 40% CH3OH+60% H2O, flow rate 2 mL/min, UV absorbance at 345 nm, DMXAA @ COF group and PBS group were treated the same. As shown in fig. 6(c), multifunctional boron-rich nano targeting agent DM was injected&The content of DMXAA in the brain glioma of Ce6@ COF-Ang1 reaches 148.79 ppm.
The results indicate that the targeted group boron-rich nano-formulation is able to cross the cell membrane more rapidly and accumulate inside the cell via the lysosomal pathway than the non-targeted group nano-formulation. In a mouse brain glioma in-situ model, a living body imaging system is used for observing that the fluorescence intensity of a mouse brain tumor part of a targeting boron-rich nano preparation group is obviously higher than that of a non-targeting boron-rich nano preparation group and a free fluorescence probe group after intravenous injection of a boron-rich nano preparation for 2 hours. Grinding and analyzing normal brain tissue and glioma tissue, and collecting glioma tissue10The content of B atoms and DMXAA is far higher than the distribution in normal brain tissue, and the treatment requirements of BNCT are met (10B > 20 ppm), achieving the targeted radiation and immune combination therapy requirements of BNCT.
Claims (9)
1. The multifunctional boron-rich nano targeting preparation based on the covalent organic framework material is characterized in that the multifunctional boron-rich nano targeting preparation is a nano-drug suspension with the diameter of 80-180 nm, which is self-assembled by a boron-rich covalent organic framework material COF loaded with a drug and a photosensitizer and a target;
the boron-rich covalent organic framework material COF is synthesized by taking terephthalic acid diboronic acid and (3-aminopropyl) -triethoxysilane as raw materials through a tube-sealing solvothermal method;
the medicine is selected from 2, 5-pentoxifylline, adriamycin and paclitaxel;
the photosensitizer is selected from chlorin e6 (Ce 6), IR780 dye;
the target comprises DSPE-PEG2k-X and DSPE-PEG2k,DSPE-PEG2k-X has the following structure:
wherein X is selected from the following structures:
each milliliter of the suspension contains 3-5 mg of boron-rich covalent organic framework material COF, and each milliliter of the suspension is loaded with 0.25-1 mg of photosensitizer, 0.5-2 mg of medicine and 1.2-12 mg of DSPE-PEG2k-X。
2. The preparation method of the multifunctional boron-rich nano-targeting preparation based on the covalent organic framework material as claimed in claim 1, characterized by comprising the following steps:
synthesizing a boron-rich covalent organic framework material COF by using terephthalic acid diborate, (3-aminopropyl) -triethoxysilane as a raw material and mesitylene and 1, 4-dioxane as solvents by a sealed tube solvothermal method;
II stepMixing the prepared boron-rich covalent organic framework material COF with a DMSO solution in which a medicine and a photosensitizer are dissolved, and performing ultrasonic oscillation to obtain a boron-rich covalent organic framework material COF loaded with the medicine and the photosensitizer;
step IIIThe reaction solution is added with DSPE-PEG dissolved with a target substance2k-X and DSPE-PEG2kThe ethanol solution is used for stripping the block-shaped boron-rich covalent organic framework material COF under the ultrasonic action, and deionized water is slowly added to emulsify the block-shaped boron-rich covalent organic framework material COF;
fourthly, the stepDialyzing the obtained nanosheet suspension in a phosphate buffer solution to obtain a suspension of the nano-drug with the diameter of 80-180 nm;
the definition of the medicine, the photosensitizer and the target substance is the same as the claim 1.
3. The method for preparing the multifunctional boron-rich nano-targeting preparation based on the covalent organic framework material as claimed in claim 2, wherein the steps are as followsThe method comprises the steps of treating a mixed solvent of mesitylene and 1, 4-dioxane by a three-time freeze-pump-melt circulation method, drying the prepared boron-rich covalent organic framework material COF in vacuum to obtain white solid powder, wherein the molar ratio of terephthalic acid diboronic acid to (3-aminopropyl) -triethoxysilane is 1: 3-4.5, and the volume ratio of the mesitylene to 1, 4-dioxane is 1: 1-1.5.
4. The covalent organic framework material-based multiple functions of claim 2The preparation method of the boron-rich nano targeting preparation is characterized by comprising the following stepsThe mass ratio of the traditional Chinese medicine, the photosensitizer and the boron-rich covalent organic framework material COF is 1-4: 2-8: 12-20.
5. The method for preparing the multifunctional boron-rich nano-targeting formulation based on covalent organic framework material according to claim 2, wherein the step ofThe mass ratio of the middle target to the boron-rich covalent organic framework material COF (chip on film) is 3: 1-5: 1, and the DSPE-PEG (polyethylene glycol) is2kThe mass fraction of X in the target is 10-90%.
8. The multifunctional boron-rich nano-targeting formulation based on covalent organic framework materials according to claim 1, characterized in that it is used for the preparation of anti-tumor drugs.
9. The multifunctional boron-rich nano-targeting formulation based on covalent organic framework material according to claim 8, wherein said tumor comprises brain glioma, breast cancer, ovarian cancer, liver cancer, kidney cancer, lung cancer, colon cancer, bladder cancer, pancreatic cancer, uterine cancer, stomach cancer, rectal cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111291736.5A CN114010783B (en) | 2021-11-03 | 2021-11-03 | Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111291736.5A CN114010783B (en) | 2021-11-03 | 2021-11-03 | Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114010783A true CN114010783A (en) | 2022-02-08 |
CN114010783B CN114010783B (en) | 2022-10-18 |
Family
ID=80060175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111291736.5A Active CN114010783B (en) | 2021-11-03 | 2021-11-03 | Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114010783B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115192708A (en) * | 2022-07-07 | 2022-10-18 | 安徽医科大学 | Nano composite material loaded with anti-tumor drug, nano drug-loaded system, preparation and application |
CN115449088A (en) * | 2022-10-28 | 2022-12-09 | 中国人民解放军陆军特色医学中心 | High-porosity COF (chip on film) nano-particles, preparation method thereof and application of high-porosity COF nano-particles as drug carrier |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664858A (en) * | 2016-01-28 | 2016-06-15 | 武汉大学 | Preparation method of novel open tubular electrochromatography column based on covalent organic framework material COF-1 |
CN105749280A (en) * | 2016-04-07 | 2016-07-13 | 沈阳大学 | Preparation method and application of tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy |
CN108210506A (en) * | 2017-12-22 | 2018-06-29 | 上海交通大学 | PH is responded and the Nano medication delivery vector of polypeptide targeting and its preparation and application |
US20190344530A1 (en) * | 2018-05-14 | 2019-11-14 | Mitsubishi Polyester Film Gmbh | Biaxially Oriented Matt Polyester Film with Increased Coefficient of Friction |
US20200271740A1 (en) * | 2017-05-26 | 2020-08-27 | Riken | Nanosheet-containing orientation agent for nmr measurement |
CN113563601A (en) * | 2021-08-18 | 2021-10-29 | 苏州大学 | Cation-deficient ZIF porous material and preparation method and application thereof |
-
2021
- 2021-11-03 CN CN202111291736.5A patent/CN114010783B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664858A (en) * | 2016-01-28 | 2016-06-15 | 武汉大学 | Preparation method of novel open tubular electrochromatography column based on covalent organic framework material COF-1 |
CN105749280A (en) * | 2016-04-07 | 2016-07-13 | 沈阳大学 | Preparation method and application of tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy |
US20200271740A1 (en) * | 2017-05-26 | 2020-08-27 | Riken | Nanosheet-containing orientation agent for nmr measurement |
CN108210506A (en) * | 2017-12-22 | 2018-06-29 | 上海交通大学 | PH is responded and the Nano medication delivery vector of polypeptide targeting and its preparation and application |
US20190344530A1 (en) * | 2018-05-14 | 2019-11-14 | Mitsubishi Polyester Film Gmbh | Biaxially Oriented Matt Polyester Film with Increased Coefficient of Friction |
CN113563601A (en) * | 2021-08-18 | 2021-10-29 | 苏州大学 | Cation-deficient ZIF porous material and preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
GUIYANG ZHANG等: "Water-dispersible PEG-curcumin/aminefunctionalized covalent organic framework nanocomposites as smart carriers for in vivo drug delivery", 《NATURE COMMUNICATIONS》 * |
LEI GE等: "Light-Activated Hypoxia-Sensitive Covalent Organic Framework for Tandem-Responsive Drug Delivery", 《NANO LETTERS》 * |
刘富林等: "《艾滋病病毒和肿瘤病毒的致病分子生物学基础和治疗前景》", 31 March 1995, 北京工业大学出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115192708A (en) * | 2022-07-07 | 2022-10-18 | 安徽医科大学 | Nano composite material loaded with anti-tumor drug, nano drug-loaded system, preparation and application |
CN115192708B (en) * | 2022-07-07 | 2024-02-27 | 安徽医科大学 | Nanocomposite loaded with antitumor drug, nano drug-carrying system, preparation and application |
CN115449088A (en) * | 2022-10-28 | 2022-12-09 | 中国人民解放军陆军特色医学中心 | High-porosity COF (chip on film) nano-particles, preparation method thereof and application of high-porosity COF nano-particles as drug carrier |
CN115449088B (en) * | 2022-10-28 | 2023-06-16 | 中国人民解放军陆军特色医学中心 | High-pore COF nano-particle, preparation method thereof and application thereof as drug carrier |
Also Published As
Publication number | Publication date |
---|---|
CN114010783B (en) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Biomimetic nanoparticles camouflaged in cancer cell membranes and their applications in cancer theranostics | |
CN114010783B (en) | Multifunctional boron-rich nano targeting preparation based on covalent organic framework material, and preparation method and application thereof | |
Wang et al. | Enhanced-fluorescent imaging and targeted therapy of liver cancer using highly luminescent carbon dots-conjugated foliate | |
Peng et al. | A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy | |
Lee et al. | pH-sensitive short worm-like micelles targeting tumors based on the extracellular pH | |
Liao et al. | A chitosan/mesoporous silica nanoparticle-based anticancer drug delivery system with a “tumor-triggered targeting” property | |
Ye et al. | Microenvironment-responsive chemotherapeutic nanogels for enhancing tumor therapy via DNA damage and glutathione consumption | |
CN112516109A (en) | Mesenchymal stem cell-based fusion cancer cell membrane bionic nanoparticle and preparation method thereof | |
CN111544598B (en) | Ferritin nanoparticle loaded with Survivin double inhibitors as well as preparation method and application thereof | |
Wu et al. | Fluorescence imaging-guided multifunctional liposomes for tumor-specific phototherapy for laryngeal carcinoma | |
Zeng et al. | Synthesis, characterization, and evaluation of a novel amphiphilic polymer RGD-PEG-Chol for target drug delivery system | |
Nguyen et al. | Recent advances in extracellular vesicle-based organic nanotherapeutic drugs for precision cancer therapy | |
CN113663079A (en) | Carrier-free self-assembly nano particle and preparation method and application thereof | |
Zhang et al. | Co-delivery of rose bengal and doxorubicin nanoparticles for combination photodynamic and chemo-therapy | |
CN107266384B (en) | N- carboxyl inner-acid anhydride monomer and polyaminoacid based on 2- aminohexadecanoic acid and preparation method thereof | |
Fan et al. | Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors | |
He et al. | NIR-II absorptive dithienopyrrole-thiadiazolobenzotriazole conjugated polymer for photoacoustic imaging-guided glioblastoma multiforme photothermal therapy | |
Kou et al. | Erythrocyte membrane-camouflaged DNA-functionalized upconversion nanoparticles for tumor-targeted chemotherapy and immunotherapy | |
Mo et al. | The study of exosomes-encapsulated mPEG-PLGA polymer drug-loaded particles for targeted therapy of liver cancer | |
Zhang et al. | Mitochondria-targeted liposome-enveloped covalent organic framework co-delivery system for enhanced tumor therapy | |
CN109675052B (en) | Efficient targeting conjugate triggered by biological click, and multi-component composition, preparation method and application thereof | |
CN114225029B (en) | Nanoparticle with sound-sensitive response and application thereof | |
Shen et al. | Recent advances in biological membrane-based nanomaterials for cancer therapy | |
CN109364024A (en) | A kind of target polymer preparation method, the preparation method and application of target liposomes, liposome targeting preparation | |
CN112891339A (en) | Heme nano vesicle for encapsulating artemisinin, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |